Bone Scan Index predicts outcome in patients with metastatic hormone‐sensitive prostate cancer

Objective To evaluate the Bone Scan Index (BSI) for prediction of castration resistance and prostate cancer‐specific survival (PCSS). In this retrospective study, we used novel computer‐assisted software for automated detection/quantification of bone metastases by BSI. Patients with prostate cancer...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2016-05, Vol.117 (5), p.748-753
Main Authors: Poulsen, Mads H., Rasmussen, Janne, Edenbrandt, Lars, Høilund‐Carlsen, Poul F., Gerke, Oke, Johansen, Allan, Lund, Lars
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Algorithms
Automation
Bone Density
Bone Neoplasms - secondary
bone scan index
BSI
Confidence intervals
follow‐up
Humans
Male
Metastasis
Middle Aged
Multivariate analysis
Neoplasm Grading
Neoplasm Staging
Prognosis
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Radiographic Image Interpretation, Computer-Assisted
Radionuclide Imaging
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the Bone Scan Index (BSI) for prediction of castration resistance and prostate cancer‐specific survival (PCSS). In this retrospective study, we used novel computer‐assisted software for automated detection/quantification of bone metastases by BSI. Patients with prostate cancer are M‐staged by whole‐body bone scintigraphy (WBS) and categorised as M0 or M1. Within the M1 group, there is a wide range of clinical outcomes. The BSI was introduced a decade ago providing quantification of bone metastases by estimating the percentage of bone involvement. Being too time consuming, it never gained widespread clinical use. Patients and Methods In all, 88 patients with prostate cancer awaiting initiation of androgen‐deprivation therapy due to metastases were included. WBS was performed using a two‐headed γ‐camera. BSI was obtained using the automated platform EXINI bone (EXINI Diagnostics AB, Lund, Sweden). In Cox proportional hazard models, time to castration‐resistant prostate cancer (CRPC) and PCSS were modelled as the dependent variables, whereas prostate‐specific antigen (PSA) level, Gleason score and BSI were used as explanatory factors. For Kaplan–Meier estimates, BSI groups were dichotomously split into: BSI
ISSN:1464-4096
1464-410X
DOI:10.1111/bju.13160